drugset / Trial / NCT00208234
Effect of Xolair on Airway Hyperresponsiveness
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine if Xolair can reduce the abnormal increase in limitation to airflow in patients with asthma in a relatively short time period. Another purpose is to determine if Xolair will decrease the amount of inflammation in the lungs of an asthmatic patient in the same time period.
Timeline
- Start
- 2004-01
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | 0.016 mg/kg | — |